Weifang Ruze New Material Co., Ltd.

 

Your Aspiration is Our Commitment

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsAntineoplastic Drugs

Lapatinib 231277-92-2 Antineoplastic Drugs Yellow Solid Appearance

Ruze supply good service, thanks.

—— Gaurav

I'm Online Chat Now

Lapatinib 231277-92-2 Antineoplastic Drugs Yellow Solid Appearance

China Lapatinib 231277-92-2  Antineoplastic Drugs Yellow Solid Appearance supplier
Lapatinib 231277-92-2  Antineoplastic Drugs Yellow Solid Appearance supplier Lapatinib 231277-92-2  Antineoplastic Drugs Yellow Solid Appearance supplier

Large Image :  Lapatinib 231277-92-2 Antineoplastic Drugs Yellow Solid Appearance

Product Details:

Place of Origin: Weifang,China
Brand Name: RuzE
Model Number: TC-5006

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Delivery Time: 5-10work days
Payment Terms: L/C, T/T, Western Union, MoneyGram
Contact Now
Detailed Product Description
Product Name: Lapatinib Synonyms: Lapatinib;n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-;Lapati
CAS: 231277-92-2 MF: C29H26ClFN4O4S
MW: 581.0575432 EINECS: 1806241-263-5

Weifang Ruze New Material Co.,LTD a China supplier of lapatinib(CAS No.: 231277-92-2),CAS 231277-92-2 offers for your requirements of RND, evaluation, pilots and commercial along with supportive technical package required for evaluation.


Lapatinib 231277-92-2  Antineoplastic Drugs Yellow Solid Appearance

             

                                                                           lapatinib 231277-92-2

 

[PRODUCT NAME]: lapatinib

[CATALOG NUMBER]:

[CAS NUMBER]:231277-92-2

[MOLECULAR FORMULA]:C29H26ClFN4O4S

[MOLECULAR WEIGHT]:581.05800

[BATCH NO]: 20190226

[TEST]:SPECIFICATION

[APPEARANCE]: Yellow solid

[ASSAY]: 99%min[WATER]: 0.5%max


Lapatinib Chemical Properties

CAS DataBase Reference 231277-92-2(CAS DataBase Reference)

Safety Information

HS Code 29349990

 

Lapatinib Usage And Synthesis

Indications and Usage Lapatinib is a drug targeting breast cancer developed by British GlaxoSmithKline Co.
Human ErbB receptors belong to the type I tyrosine kinase (TK) receptor family, including ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). The ErbB-1 (EGFR) and ErbB-2 (HER-2) receptors are often overexpressed or otherwise altered in cancer patients. Human epidermal growth factor receptor 2 (ErbB-2, HER-2) is known to be a human oncogene closely related with breast cancer. Its high expression in breast cancer often predicts lymph node metastasis and poor tumor differentiation, with poor prognosis. HER-2 is one of the target molecules for breast cancer-specific therapy. Lapatinib can act simultaneously on both Her-1 Her-2. The biological effects of this method inhibiting the proliferation and growth of tumor cells are much larger than only acting on one target. The combination of Lapatinib with Capecitabine is used to treat patients with advanced or metastatic breast cancer with overexpression of human epidermal receptor2, already treated with anthracyclines, paclitaxel, and trastuzumab. Clinical trials have shown that Lapatinib also effectively treats HER2-type cancer patients with Herceptin resistance.
Mechanisms of Action Lapatinib is a tyrosine kinase inhibitor which can effectively inhibit the tyrosine kinase activity of human epidermal growth factor receptors 1 and 2 (ErbB1, ErbB2). It can uniquely act in a variety of ways, ensuring that breast cancer cells cannot receive growth signals. It inhibits intracellular EGFR (ErbB-1) and HER2 (ErbB-2) ATP sites, preventing tumor cell phosphorylation and activation, blocking down-regulation signals through the homogeneity and heterogeneity of EGFR (ErbB-1) and HER2 (ErbB-1) dimerization.
Description Lapatinib, a new member of the 4-anilinoquinazoline class of RTK inhibitors (RTKIs), was launched as an oral treatment for breast cancer. Lapatinib has dual affinity for EGFR and HER2 tyrosine kinases. It is indicated in combination with capecitabine for treating patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Previously marketed drugs from the 4-anilinoquinazoline class include erlotinib (Tarceva) and gefitinib (IressaTM), both of which are indicated for treating non-small-cell lung cancer (NSCLC). As with erlotinib and gefitinib, To Market, To Market 2007 475 lapatinib is an ATP-competitive kinase inhibitor. It inhibits the tyrosine kinase activity EGFR and HER-2 with apparent Ki values of 3 and 13 nM, respectively, and has slow off-rate kinetics (t1/2X300 min).
In addition, dividing the daily dose of lapatinib results in approximately 2-fold higher exposure at steady state compared to the same total dose administered once daily.
The chemical synthesis of lapatinib entails the condensation of 4-chloro-6-iodoquinazoline and 3-chloro-4-(3-fluorobenzyloxy)aniline to produce a diaryl amine intermediate followed by Stille coupling of the iodo group with 5-dioxolanyl-2-(tributylstannyl)furan and subsequent acid hydrolysis of the cyclic ketal to the corresponding aldehyde. Finally, reductive amination of the aldehyde intermediate with 2-(methanesulfonyl) ethylamine in the presence of sodium triacetoxyborohydride produces lapatinib. .
Originator GSK (US)
Uses Lapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
Uses Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
Uses antineoplastic, tyrosine kinase inhibitor
Uses An antineoplastic agent used in breast cancer research
Brand name Tykerb

Lapatinib 231277-92-2  Antineoplastic Drugs Yellow Solid AppearanceLapatinib 231277-92-2  Antineoplastic Drugs Yellow Solid Appearance

Lapatinib 231277-92-2  Antineoplastic Drugs Yellow Solid AppearanceLapatinib 231277-92-2  Antineoplastic Drugs Yellow Solid AppearanceLapatinib 231277-92-2  Antineoplastic Drugs Yellow Solid Appearance

 

Lapatinib 231277-92-2  Antineoplastic Drugs Yellow Solid Appearance

Weifang Ruze New Material Co.,LTD supply free sample and datebase on lapatinib(CAS No.: 231277-92-2), if you want futher information about lapatinib(CAS No.: 231277-92-2), please feel free to contract us.

Contact Details
Weifang Ruze New Material Co., Ltd.

Contact Person: Ruze01

Send your inquiry directly to us (0 / 3000)